Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease.
Both represent chronic inflammation of the gastrointestinal tract, which displays …

Background Vedolizumab [VDZ] is an anti-integrin monoclonal antibody effective in
ulcerative colitis [UC] and Crohn's disease [CD]. Several real-world experience [RWE] …

Background Women with inflammatory bowel diseases (IBD) often receive biologicals
during pregnancy to maintain disease remission. Data on outcome of vedolizumab‐exposed …

Two new biological drugs (vedolizumab and ustekinumab) and one small molecule
(tofacitinib) have been recently approved for the treatment of inflammatory bowel disease …

An increasing and early-onset use of immunosuppressives and biologics has become more
frequently seen among patients with inflammatory bowel diseases (IBD) and rheumatic …

Introduction: The peak age of diagnosis of inflammatory bowel disease (IBD) occurs during
childbearing years, therefore management of IBD during pregnancy is a frequent …

Abstract Background and Aims Vedolizumab is an IgG1 anti-α4β7 integrin antibody
approved for the treatment of inflammatory bowel diseases [IBD], but without clear safety …

Background Little is known about the consequences of intrauterine exposure to, and the
post‐natal clearance of, vedolizumab. Aims To investigate the levels of vedolizumab in …

Background Research has indicated a lack of disease-specific reproductive knowledge
among patients with Inflammatory Bowel Disease (IBD) and this has been associated with …

Abstract Background and Aim Vedolizumab is a novel monoclonal antibody used in patients
with inflammatory bowel disease, often affecting women of child‐bearing age. We aimed to …